Moreover, the GFAP level and the Aβ42/P-tau181 ratio showed potential diagnostic and progression monitoring value, respectively, for Alzheimer’s disease patients. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.